Summary by Moomoo AI
On December 31, 2023, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a 6.71% ownership stake in Tonix Pharmaceuticals Holding Corp., amounting to 3,770,000 shares. The filing indicates that Armistice Capital, LLC, a Delaware-based investment adviser, and Steven Boyd, a U.S. citizen, share voting and dispositive power over these shares. The shares are held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The Master Fund is an investment advisory client of Armistice Capital and is entitled to dividends or sale proceeds from the securities. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.